Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer

Cancer

Volumn 118, Issue 14, 2012, Pages 3579-3586

  Lee, June Koo ^a   Park, Heae Surng ^a   Kim, Dong Wan ^a,b   Kulig, Kimary ^c   Kim, Tae Min ^a,b   Lee, Se Hoon ^a,b   Jeon, Yoon Kyung ^a   Chung, Doo Hyun ^a   Heo, Dae Seog ^a,b   Kim, Woo Ho ^a   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c PFIZER INC   (United States)

Author keywords

anaplastic lymphoma kinase; epidermal growth factor receptor; nonsmall cell lung carcinoma; overall survival; tyrosine kinase inhibitor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; ALK GENE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOUTH KOREA; WILD TYPE;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84863309678     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26668     Document Type: Article

References (32)

1. Ramalingam SS, Owonikoko TK, Khuri FR,. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61: 91-112.
2. Pao W, Girard N,. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12: 175-180.
3. Horn L, Pao W,. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 2009; 27: 4232-4235.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566. (Pubitemid 47206930)
5. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008; 105: 19893-19897.
6. Mano H,. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008; 99: 2349-2355.
7. Weinstein IB,. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002; 297: 63-64. (Pubitemid 34743088)
8. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 1 14: 4275-4283, 2008.
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
10. Gerber DE, Minna JD,. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010; 18: 548-551.
11. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363: 1734-1739.
12. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-4253.
13. Sasaki T, Rodig SJ, Chirieac LR, Janne PA,. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46: 1773-1780.
14. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115: 1723-1733.
15. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15: 5216-5223.
16. Kelleher FC, McDermott R,. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer. 2010; 46: 2357-2368.
17. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;: 889-897.
18. Ou SH, Ziogas A, Zell JA,. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol. 2010; 5: 420-427.
19. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3: 13-17.
20. Cooper WA, O'Toole S, Boyer M, Horvath L, Mahar A,. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 2011; 43: 103-115.
21. Camidge DR, Hirsch FR, Varella-Garcia M, Franklin WA,. Finding ALK-positive lung cancer: what are we really looking for? J Thorac Oncol. 2011; 6: 411-413.
22. Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol. 2011; 6: 905-912.
23. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16: 5581-5590.
24. Antoniu SA,. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer (N Engl J Med. 2010;363:1693-1703). Expert Opin Ther Targets. 2011; 15: 351-353.
25. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139. (Pubitemid 38637993)
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
27. Colby TV, Noguchi M, Henschke C, Vazquez MF, Geisinger K, Yokose T,. Adenocarcinoma. In:, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization of Tumours. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004: 35-44.
28. Shaw AT, Solomon B,. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011; 17: 2081-2086.
29. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011; 6: 774-780.
30. Lee JO, Kim TM, Lee SH, et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 2011; 6: 1474-1480.
31. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011; 6: 466-472.
32. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the Surveillance, Epidemiology, and End Results registry versus independent review. J Natl Cancer Inst. 2004; 96: 1105-1107. (Pubitemid 39172413)